To evaluate whether a commercial pre-plan feasibility tool can predict treatment plan achievability and performance against TG-218–recommended measurement-based IMRT QA criteria and TG-219 secondary dose calculation agreement.
Christopher S. Melhus, PhDElizabeth Meyer, MS
Therapy Physics